Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) from a strong sell rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Several other analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Lake Street Capital started coverage on shares of Verrica Pharmaceuticals in a report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Verrica Pharmaceuticals has an average rating of “Hold” and an average target price of $12.67.

Check Out Our Latest Stock Report on VRCA

Verrica Pharmaceuticals Price Performance

VRCA opened at $4.60 on Friday. The business has a fifty day moving average of $5.04 and a 200 day moving average of $5.69. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. The stock has a market cap of $79.03 million, a P/E ratio of -2.75 and a beta of 1.49.

Institutional Trading of Verrica Pharmaceuticals

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Armistice Capital LLC boosted its position in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Free Report) by 75.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,118,925 shares of the company’s stock after purchasing an additional 479,732 shares during the quarter. Armistice Capital LLC owned about 7.00% of Verrica Pharmaceuticals worth $9,298,000 as of its most recent filing with the Securities & Exchange Commission. 42.45% of the stock is currently owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

(Get Free Report)

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases. The company’s work centers on topical therapies designed to address conditions for which patients and healthcare providers have limited treatment options.

Verrica’s lead product, YCANTHE (cantharidin) topical solution, 0.7%, is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children ages 2 and older.

See Also